LT3894411T - 7-fenoksi-n-(3-azabiciklo[3.2.1]oktan-8-il)-6,7-dihidro-5h-pirolo [1,2-b][1,2,4]triazol-2-amino dariniai ir susiję junginiai kaip gama sekretazės moduliatoriai alzheimerio ligai gydyti - Google Patents
7-fenoksi-n-(3-azabiciklo[3.2.1]oktan-8-il)-6,7-dihidro-5h-pirolo [1,2-b][1,2,4]triazol-2-amino dariniai ir susiję junginiai kaip gama sekretazės moduliatoriai alzheimerio ligai gydytiInfo
- Publication number
- LT3894411T LT3894411T LTEPPCT/EP2019/084538T LTEP2019084538T LT3894411T LT 3894411 T LT3894411 T LT 3894411T LT EP2019084538 T LTEP2019084538 T LT EP2019084538T LT 3894411 T LT3894411 T LT 3894411T
- Authority
- LT
- Lithuania
- Prior art keywords
- octan
- azabicyclo
- pyrrolo
- triazol
- alzheimer
- Prior art date
Links
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212199 | 2018-12-13 | ||
| PCT/EP2019/084538 WO2020120521A1 (en) | 2018-12-13 | 2019-12-11 | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3894411T true LT3894411T (lt) | 2024-08-26 |
Family
ID=64665266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2019/084538T LT3894411T (lt) | 2018-12-13 | 2019-12-11 | 7-fenoksi-n-(3-azabiciklo[3.2.1]oktan-8-il)-6,7-dihidro-5h-pirolo [1,2-b][1,2,4]triazol-2-amino dariniai ir susiję junginiai kaip gama sekretazės moduliatoriai alzheimerio ligai gydyti |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US12195470B2 (lt) |
| EP (2) | EP4424370A3 (lt) |
| JP (2) | JP7566745B2 (lt) |
| KR (1) | KR102910810B1 (lt) |
| CN (2) | CN117946116A (lt) |
| AR (1) | AR116906A1 (lt) |
| AU (1) | AU2019395774B2 (lt) |
| BR (1) | BR112021009443A2 (lt) |
| CA (1) | CA3117870A1 (lt) |
| CL (1) | CL2021001547A1 (lt) |
| CO (1) | CO2021006837A2 (lt) |
| CR (1) | CR20210305A (lt) |
| DK (1) | DK3894411T3 (lt) |
| ES (1) | ES2986688T3 (lt) |
| FI (1) | FI3894411T3 (lt) |
| HR (1) | HRP20241097T1 (lt) |
| HU (1) | HUE067669T2 (lt) |
| IL (2) | IL310081A (lt) |
| LT (1) | LT3894411T (lt) |
| MA (1) | MA54447B1 (lt) |
| MX (1) | MX2021006761A (lt) |
| MY (1) | MY208077A (lt) |
| PE (1) | PE20211776A1 (lt) |
| PH (1) | PH12021551387A1 (lt) |
| PL (1) | PL3894411T3 (lt) |
| PT (1) | PT3894411T (lt) |
| RS (1) | RS65821B1 (lt) |
| SG (1) | SG11202103340PA (lt) |
| SI (1) | SI3894411T1 (lt) |
| TW (1) | TWI831892B (lt) |
| UA (1) | UA129650C2 (lt) |
| WO (1) | WO2020120521A1 (lt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3894411T (lt) * | 2018-12-13 | 2024-08-26 | F. Hoffmann-La Roche Ag | 7-fenoksi-n-(3-azabiciklo[3.2.1]oktan-8-il)-6,7-dihidro-5h-pirolo [1,2-b][1,2,4]triazol-2-amino dariniai ir susiję junginiai kaip gama sekretazės moduliatoriai alzheimerio ligai gydyti |
| US12275709B2 (en) | 2018-12-27 | 2025-04-15 | Hoffmann-La Roche Inc. | Process for the preparation of exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate |
| AU2024312554A1 (en) | 2023-06-19 | 2025-12-18 | F. Hoffmann-La Roche Ag | Process for the preparation of a chiral pyrrolo triazole alcohol |
| WO2025228863A1 (en) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative |
| WO2026061922A1 (en) | 2024-09-17 | 2026-03-26 | F. Hoffmann-La Roche Ag | Deuterated bicyclic heteroaryl derivatives |
| WO2026074067A1 (en) | 2024-10-04 | 2026-04-09 | F. Hoffmann-La Roche Ag | Solid forms of a gamma-secretase modulator |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994349A (en) | 1997-10-27 | 1999-11-30 | Howard University | 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives |
| EP1422217A3 (en) | 1998-04-01 | 2004-06-16 | Cardiome Pharma Corp. | Aminocyclohexyl ether compounds and uses thereof |
| AU2528900A (en) | 1999-02-12 | 2000-08-29 | Nortran Pharmaceuticals Inc. | Cycloalkyl amine compounds and uses thereof |
| US7507545B2 (en) | 1999-03-31 | 2009-03-24 | Cardiome Pharma Corp. | Ion channel modulating activity method |
| US6448246B1 (en) | 1999-05-25 | 2002-09-10 | Neurogen Corporation | Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands |
| EP1218003A4 (en) | 1999-09-13 | 2004-02-11 | David M Swope | COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY |
| US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
| US7499263B2 (en) | 2005-08-30 | 2009-03-03 | Doosan Infracore Co., Ltd. | Mobile power source cable connection system and method |
| US8703753B2 (en) | 2005-09-15 | 2014-04-22 | Biomas Ltd. | Use of tellurium compounds for the treatment of actinic keratosis |
| AU2008250436B2 (en) | 2007-05-11 | 2013-03-28 | F. Hoffmann-La Roche Ag | Hetarylanilines as modulators for amyloid beta |
| BRPI0817433A2 (pt) | 2007-10-19 | 2015-06-16 | Janssen Pharmaceutica Nv | Moduladores de gama-secretase piperidinila e piperazinila |
| US8673900B2 (en) | 2008-11-13 | 2014-03-18 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| TW201035101A (en) | 2009-02-26 | 2010-10-01 | Eisai R&D Man Co Ltd | Nitrogen-containing fused heterocyclic compound |
| WO2010138901A1 (en) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| EP2443657A4 (en) | 2009-09-04 | 2013-07-31 | Hewlett Packard Development Co | MEMRISTORS BASED ON MIXED METAL VALVE COMPOUNDS |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| ES2555167T3 (es) | 2011-07-15 | 2015-12-29 | Janssen Pharmaceuticals, Inc. | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa |
| US9637491B2 (en) | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
| JP6831372B2 (ja) | 2015-09-09 | 2021-02-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋ピペリジン誘導体 |
| WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| JP7012715B2 (ja) | 2016-06-27 | 2022-01-28 | エフ．ホフマン－ラ ロシュ アーゲー | γ－セクレターゼモジュレーターとしてのトリアゾロピリジン |
| AR109829A1 (es) | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| EP3535266B1 (en) * | 2016-11-01 | 2021-12-29 | F. Hoffmann-La Roche AG | Bicyclic heteroaryl derivatives |
| CN109790149B (zh) * | 2016-11-08 | 2022-05-17 | 豪夫迈·罗氏有限公司 | 苯氧基三唑类化合物 |
| CN110337291A (zh) | 2016-12-16 | 2019-10-15 | 帕珀莱恩医疗公司 | 治疗耳蜗突触病变的方法 |
| CN111417636B (zh) | 2018-01-22 | 2023-09-26 | 豪夫迈·罗氏有限公司 | 三唑并-氮杂䓬衍生物 |
| LT3894411T (lt) * | 2018-12-13 | 2024-08-26 | F. Hoffmann-La Roche Ag | 7-fenoksi-n-(3-azabiciklo[3.2.1]oktan-8-il)-6,7-dihidro-5h-pirolo [1,2-b][1,2,4]triazol-2-amino dariniai ir susiję junginiai kaip gama sekretazės moduliatoriai alzheimerio ligai gydyti |
-
2019
- 2019-12-11 LT LTEPPCT/EP2019/084538T patent/LT3894411T/lt unknown
- 2019-12-11 MY MYPI2021001956A patent/MY208077A/en unknown
- 2019-12-11 CA CA3117870A patent/CA3117870A1/en active Pending
- 2019-12-11 IL IL310081A patent/IL310081A/en unknown
- 2019-12-11 KR KR1020217017774A patent/KR102910810B1/ko active Active
- 2019-12-11 HR HRP20241097TT patent/HRP20241097T1/hr unknown
- 2019-12-11 JP JP2021533563A patent/JP7566745B2/ja active Active
- 2019-12-11 IL IL283823A patent/IL283823B2/en unknown
- 2019-12-11 CN CN202311792520.6A patent/CN117946116A/zh active Pending
- 2019-12-11 PL PL19824250.5T patent/PL3894411T3/pl unknown
- 2019-12-11 EP EP24177200.3A patent/EP4424370A3/en active Pending
- 2019-12-11 ES ES19824250T patent/ES2986688T3/es active Active
- 2019-12-11 BR BR112021009443-1A patent/BR112021009443A2/pt unknown
- 2019-12-11 DK DK19824250.5T patent/DK3894411T3/da active
- 2019-12-11 SG SG11202103340PA patent/SG11202103340PA/en unknown
- 2019-12-11 PT PT198242505T patent/PT3894411T/pt unknown
- 2019-12-11 UA UAA202103248A patent/UA129650C2/uk unknown
- 2019-12-11 PH PH1/2021/551387A patent/PH12021551387A1/en unknown
- 2019-12-11 MA MA54447A patent/MA54447B1/fr unknown
- 2019-12-11 PE PE2021000726A patent/PE20211776A1/es unknown
- 2019-12-11 FI FIEP19824250.5T patent/FI3894411T3/fi active
- 2019-12-11 EP EP19824250.5A patent/EP3894411B1/en active Active
- 2019-12-11 CN CN201980076253.8A patent/CN113179641B/zh active Active
- 2019-12-11 RS RS20240883A patent/RS65821B1/sr unknown
- 2019-12-11 CR CR20210305A patent/CR20210305A/es unknown
- 2019-12-11 AU AU2019395774A patent/AU2019395774B2/en active Active
- 2019-12-11 HU HUE19824250A patent/HUE067669T2/hu unknown
- 2019-12-11 US US17/413,413 patent/US12195470B2/en active Active
- 2019-12-11 MX MX2021006761A patent/MX2021006761A/es unknown
- 2019-12-11 SI SI201930802T patent/SI3894411T1/sl unknown
- 2019-12-11 WO PCT/EP2019/084538 patent/WO2020120521A1/en not_active Ceased
- 2019-12-12 AR ARP190103631A patent/AR116906A1/es unknown
- 2019-12-12 TW TW108145480A patent/TWI831892B/zh active
-
2021
- 2021-05-24 CO CONC2021/0006837A patent/CO2021006837A2/es unknown
- 2021-06-11 CL CL2021001547A patent/CL2021001547A1/es unknown
-
2024
- 2024-10-02 JP JP2024173048A patent/JP2025000919A/ja active Pending
- 2024-11-25 US US18/959,369 patent/US20250326758A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202103340PA (en) | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease | |
| IL275781A (en) | Background 1,3,4,5-Tetrahydro-2H-pyrido[4,3-B]indole for the treatment, mitigation or prevention of disorders associated with TAU aggregates such as Alzheimer's disease | |
| IL266170A (en) | A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts | |
| ZA202103099B (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| MX394094B (es) | PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS. | |
| EP3107914B8 (en) | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use | |
| HUE053704T2 (hu) | 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére | |
| HK1244483A1 (zh) | (s)-n-(5 - ((r)-2-(2，5-二氟苯基)吡咯烷-1-基) - 吡唑并[1，5-a ]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐 | |
| IL285445A (en) | Thiano[2,3-b]pyrrole[2,3-d]pyridazinone compounds and their use as pkm2 compounds for the treatment of cancer, obesity and diabetes-related disorders | |
| SG11201808559PA (en) | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | |
| SG10202110927VA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| IL291338A (en) | 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases | |
| IL286870A (en) | Hexahydro-h1-pyrazino[a-2,1]pyrazine compounds for the treatment of autoimmune disease | |
| IL267801A (en) | Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds | |
| ZA202100259B (en) | Pyrrolo[1,2-b]pyridazine derivatives | |
| IL291335A (en) | 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases | |
| SG11202002692XA (en) | Azabicyclo and diazepine derivatives for treating ocular disorders | |
| HK40040026A (en) | Heterocyclic compounds useful in the treatment of disease | |
| IL253427A0 (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose | |
| HK40007136A (en) | Fused bicyclic compounds for the treatment of disease |